| Size | Price | Stock | Qty |
|---|---|---|---|
| 10g |
|
||
| Other Sizes |
| Targets |
MIC: 110 μg/mL (S. aureus), 110 μg/mL (E. coli )[1].
4-Chloroguaiacol targets bacterial cell membranes and essential metabolic processes through its antimicrobial mechanism. As a phenol derivative, it likely disrupts microbial cell membrane integrity and inhibits enzymatic processes involving membrane-bound proteins. The compound's antimicrobial efficacy against both Gram-positive (Staphylococcus aureus) and Gram-negative (Escherichia coli) bacteria indicates a broad-spectrum mechanism of action. The antimicrobial properties are influenced by the position of the chlorine and methoxy substituents on the phenol ring. |
|---|---|
| ln Vitro |
4-Chloroguaiacol demonstrates in vitro antimicrobial activity against both Staphylococcus aureus and Escherichia coli with minimum inhibitory concentrations (MICs) of 110 μg/mL for both pathogens. As a phenol derivative, it exhibits antimicrobial efficacy and has been studied for its potential therapeutic applications. The compound's antimicrobial properties make it useful in studying bacterial and fungal inhibition. Further detailed studies on its spectrum of activity and mechanism of action would provide additional insights into its antimicrobial potential.
|
| ln Vivo |
In vivo studies for 4-Chloroguaiacol have not been extensively documented in the available literature. As a phenol derivative with antimicrobial activity, it has potential for in vivo applications in the treatment of bacterial infections. Studies in appropriate animal models would be needed to evaluate its in vivo efficacy, pharmacokinetics, and safety profile. The compound is investigated for potential therapeutic applications due to its bioactive properties. However, comprehensive in vivo data are not currently available.
|
| Enzyme Assay |
For antimicrobial susceptibility testing, 4-Chloroguaiacol is evaluated using standard broth microdilution or agar dilution methods. Serial two-fold dilutions of the compound are prepared in appropriate growth media and inoculated with standardized bacterial suspensions (e.g., Staphylococcus aureus and Escherichia coli). After incubation at 37°C for 18-24 hours, the minimum inhibitory concentration (MIC) is determined as the lowest concentration that inhibits visible bacterial growth. For fungal inhibition studies, similar methods are used with appropriate fungal strains.
|
| Cell Assay |
For cellular studies, bacterial cultures (Staphylococcus aureus and Escherichia coli) are grown in appropriate media and treated with 4-Chloroguaiacol at various concentrations. Minimum inhibitory concentration (MIC) is determined by broth microdilution following standard protocols. For cytotoxicity assessment, mammalian cell lines are treated with the compound and cell viability is measured using MTT or similar assays. Biofilm inhibition studies may be conducted using crystal violet staining. The compound's antimicrobial properties make it useful in studying bacterial and fungal inhibition.
|
| Animal Protocol |
For in vivo efficacy studies, appropriate animal models of bacterial infection would be used to evaluate 4-Chloroguaiacol. Rodents would be infected with Staphylococcus aureus or Escherichia coli and administered the compound via oral or parenteral routes at various doses. Endpoints would include survival, bacterial clearance from tissues, and histopathological analysis. However, detailed in vivo protocols for 4-Chloroguaiacol have not been extensively reported in the literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 4-Chloroguaiacol have not been fully characterized in the available literature. As a small phenol derivative, it is expected to be absorbed and metabolized through conjugation reactions. Comprehensive PK studies including bioavailability, half-life, protein binding, and tissue distribution are needed to fully understand its ADME properties. The compound is typically stored according to manufacturer recommendations.
|
| Toxicity/Toxicokinetics |
4-Chloroguaiacol is a research compound intended for laboratory use only and is not approved for human therapeutic use. As a phenol derivative with antimicrobial activity, it is useful in studying bacterial and fungal inhibition and investigated for potential therapeutic applications. Standard laboratory safety precautions should be followed when handling this compound.
|
| References |
[1]. Patrícia Fontes Pinheiro, et al. Semisynthetic Phenol Derivatives Obtained from Natural Phenols: Antimicrobial Activity and Molecular Properties. J Agric Food Chem. 2018 Jan 10;66(1):323-330.
|
| Additional Infomation |
4-Chloroguaiacol is a phenol derivative with antimicrobial activity, with MICs of 110 μg/mL against both Staphylococcus aureus and Escherichia coli. The compound is useful in studying bacterial and fungal inhibition and is investigated for potential therapeutic applications. The position of the chlorine and methoxy groups affects its reactivity and antimicrobial activity. It is for research use only and has not been approved for clinical applications.
|
| Molecular Formula |
C7H7CLO2
|
|---|---|
| Molecular Weight |
158.58
|
| Exact Mass |
158.013
|
| CAS # |
16766-30-6
|
| PubChem CID |
28050
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
242.4±20.0 °C at 760 mmHg
|
| Melting Point |
16-17 °C(lit.)
|
| Flash Point |
100.4±21.8 °C
|
| Vapour Pressure |
0.0±0.5 mmHg at 25°C
|
| Index of Refraction |
1.554
|
| LogP |
2.36
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
10
|
| Complexity |
108
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
ClC1C([H])=C([H])C(=C(C=1[H])OC([H])([H])[H])O[H]
|
| InChi Key |
FVZQMMMRFNURSH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C7H7ClO2/c1-10-7-4-5(8)2-3-6(7)9/h2-4,9H,1H3
|
| Chemical Name |
4-chloro-2-methoxyphenol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 100 mg/mL (630.60 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (15.76 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (15.76 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (15.76 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.3060 mL | 31.5298 mL | 63.0597 mL | |
| 5 mM | 1.2612 mL | 6.3060 mL | 12.6119 mL | |
| 10 mM | 0.6306 mL | 3.1530 mL | 6.3060 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
